Eris Lifesciences share news, announcements and annual reports
NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,163.60.
30 Oct: open ₹1,163.00, high ₹1,174.70, low ₹1,148.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,044 Cr353rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.67
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.87
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 31,21340.7% delivered
Eris Lifesciences share news and announcements
795 announcements, routine notices left out, newest first. Page 3 of 16.
May 2025
19 May · Board meeting
19 May · Results
15 May · Analysts
13 May · Analysts
13 May · Analysts
13 May · Board meeting
9 May · Updates
9 May · Rating
6 May · Updates
6 May · Rating
Apr 2025
29 Apr · Analysts
24 Apr · Disclosure
Mar 2025
31 Mar · Updates
20 Mar · Legal
The exchange asked on 20 Mar 2025
20 Mar · Analysts
7 Mar · Analysts
6 Mar · Updates
6 Mar · Disclosure
Feb 2025
24 Feb · Analysts
21 Feb · Business
19 Feb · Updates
11 Feb · Analysts
4 Feb · Corporate action
4 Feb · Board meeting
4 Feb · Results
4 Feb · Board meeting
Jan 2025
29 Jan · Analysts
29 Jan · Board meeting
Dec 2024
5 Dec · Analysts
4 Dec · Analysts
Nov 2024
13 Nov · Updates
12 Nov · Analysts
Oct 2024
25 Oct · General Updates
25 Oct · Results
25 Oct · Board meeting
23 Oct · General Updates
23 Oct · Analysts
22 Oct · Board meeting
14 Oct
Sep 2024
30 Sep · Updates